Kennett Square, PA, United States of America

Krishna Vaddi

USPTO Granted Patents = 10 (Patent Applications = 7)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 15 (Patent Applications = 10)

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 272(Granted Patents)

Location History:

Kenneth Square, PA (US) (2015)
Hockessin, DE (US) (2012 - 2016)
Kennett Square, PA (US) (2011 - 2020)

Company Filing History:

Incyte Holdings Corporation

patents

where one patent can have more than one assignee

Years Active: 2011-2020

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10653628 - High surface-area lyophilized compositions comprising arsenic for oral administration in patients (2020-05-19),

2. 10272045 - High surface-area lyophilized compositions comprising arsenic for oral administration in patients (2019-04-30),

3. 10111836 - High surface-area lyophilized compositions comprising arsenic for oral administration in patients (2018-10-30),

4. 9345677 - Compositions, methods and kits relating to HER-2 cleavage (2016-05-24),

5. 9206187 - Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase (2015-12-08),

6. 8946245 - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors (2015-02-03),

7. 8933086 - Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors (2015-01-13),

8. 8541425 - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors (2013-09-24),

9. 8088737 - Compositions, methods and kits relating to Her-2 cleavage (2012-01-03),

10. 7910108 - Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases (2011-03-22),

Title: Innovations of Krishna Vaddi in Cancer Treatment

Introduction

Krishna Vaddi is a notable inventor based in Kennett Square, PA (US), recognized for his significant contributions to the field of cancer treatment. With a total of 10 patents to his name, Vaddi has focused on developing innovative solutions that enhance the efficacy of cancer therapies.

Latest Patents

One of Vaddi's latest patents is titled "High surface-area lyophilized compositions comprising arsenic for oral administration in patients." This invention addresses the treatment of various malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), multiple myeloma (MM), lymphomas, glioblastoma multiforme, and breast cancer. The formulation allows for the oral administration of arsenic, which has shown promise in treating several cancers but traditionally requires daily intravenous (IV) administration. Vaddi's novel formulation facilitates systemic bioavailability comparable to that of IV administration of arsenic trioxide. The patent also includes methods for lyophilizing arsenic trioxide and preparing the oral formulation.

Career Highlights

Throughout his career, Krishna Vaddi has worked with prominent companies in the pharmaceutical industry, including Incyte Corporation and Orsenix Holdings BV. His experience in these organizations has contributed to his expertise in developing innovative cancer treatments.

Collaborations

Vaddi has collaborated with notable professionals in his field, including Jordan S. Fridman and James David Rodgers. These collaborations have likely enriched his research and development efforts.

Conclusion

Krishna Vaddi's work in developing oral formulations for arsenic treatment represents a significant advancement in cancer therapy. His innovative approach has the potential to improve patient outcomes and transform the way malignancies are treated.

This text is generated by artificial intelligence and may not be accurate.